SLNO · As filed with the SEC
Soleno Therapeutics balance sheet, by quarter
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|
| Assets | ||||
| Current assets | ||||
| Cash and cash equivalents | 133,026,000 | 70,106,000 | 246,662,000 | 76,497,000 |
| Marketable securities | 122,573,000 | 235,366,000 | 252,272,000 | 210,344,000 |
| Accounts receivable, net | 47,139,000 | 28,208,000 | 25,506,000 | 24,624,000 |
| Inventory, net | 17,308,000 | 15,024,000 | 6,674,000 | 2,355,000 |
| Prepaid expenses and other current assets | 6,330,000 | 7,110,000 | 3,739,000 | 2,969,000 |
| Total current assets | 326,376,000 | 355,814,000 | 534,853,000 | 316,789,000 |
| Long-term assets | ||||
| Property and equipment, net | 202,000 | 185,000 | 150,000 | 166,000 |
| Operating lease right-of-use assets | 3,891,000 | 2,191,000 | 2,314,000 | 2,434,000 |
| Intangible assets, net | 4,374,000 | 4,861,000 | 5,347,000 | 5,832,000 |
| Long-term marketable securities | 273,382,000 | 200,616,000 | 57,148,000 | 7,002,000 |
| Other long-term assets | 163,000 | 163,000 | 83,000 | 83,000 |
| Total assets | 608,388,000 | 563,830,000 | 599,895,000 | 332,306,000 |
| Liabilities and stockholders’ equity | ||||
| Current liabilities | ||||
| Accounts payable | 12,386,000 | 12,435,000 | 8,145,000 | 6,216,000 |
| Accrued compensation | 5,723,000 | 9,677,000 | 7,248,000 | 6,267,000 |
| Accrued clinical trial site costs | — | — | — | 1,863,000 |
| Operating lease liabilities | 1,163,000 | 726,000 | 697,000 | 676,000 |
| Accrued interest payable | — | — | — | 409,000 |
| Contingent liability for Essentialis purchase price | 13,846,000 | 20,327,000 | — | — |
| Other current liabilities | 24,931,000 | 18,198,000 | 17,163,000 | 5,512,000 |
| Total current liabilities | 58,049,000 | 61,363,000 | 33,253,000 | 20,943,000 |
| Long-term liabilities | ||||
| Contingent liability for Essentialis purchase price | — | — | 19,473,000 | 18,859,000 |
| Long-term debt, net | 49,871,000 | 49,863,000 | 49,854,000 | 49,845,000 |
| Long-term lease liabilities | 3,243,000 | 1,964,000 | 2,112,000 | 2,248,000 |
| Other long-term liabilities | 1,425,000 | 525,000 | 398,000 | 271,000 |
| Total liabilities | 112,588,000 | 113,715,000 | 105,090,000 | 92,166,000 |
| Stockholders’ equity | ||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 51,718,149 and 52,286,881 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 52,000 | 52,000 | 54,000 | 50,000 |
| Additional paid-in-capital | 897,578,000 | 881,018,000 | 969,119,000 | 740,746,000 |
| Accumulated other comprehensive income (loss) | (1,838,000) | 415,000 | 360,000 | 85,000 |
| Accumulated deficit | (399,992,000) | (431,370,000) | (474,728,000) | (500,741,000) |
| Total stockholders’ equity | 495,800,000 | 450,115,000 | 494,805,000 | 240,140,000 |
| Total liabilities and stockholders’ equity | 608,388,000 | 563,830,000 | 599,895,000 | 332,306,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.